Genmab AS (GMAB) revenue breakdown
By region, Denmark is the largest at 89% of fiscal 2025 revenue; Japan grew fastest, 496% a year over 2 years.
Revenue by region
Fiscal years, as Genmab AS reports them in its 10-K filings; fiscal 2025 total $3.7B.
| Regions | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| Denmark | $2.3B | $2.9B | $3.3B | 89% |
| Japan | $6M | $122M | $213M | 6% |
| United States | $55M | $131M | $180M | 5% |
| Netherlands | — | — | $1M | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GMAB.
Open GMAB in InvestinglyQuestions
Where does Genmab AS make its money?
In fiscal 2025, by region: Denmark $3.3B, Japan $213M, United States $180M, Netherlands $1M.
From Genmab AS's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.